Key points are not available for this paper at this time.
MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.
Mario Cazzola (Wed,) studied this question.